ATPW
CRNX icon

Ashton Thomas Private Wealth’s Crinetics Pharmaceuticals CRNX Stock Holding History

Ashton Thomas Private Wealth’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-80
Closed -$3.58K – 878
2024
Q2 		$3.58K Buy
+80
New +$3.69K ﹤0.01% 1638

Other funds holding CRNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Ashton Thomas Private Wealth's CRNX Position: Q3 2024 in Review

Ashton Thomas Private Wealth sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2024, closing a stake of 80 shares — an estimated $3.58K sold.

Ashton Thomas Private Wealth first reported a position in CRNX in Q2 2024 and held it in 1 quarter. The position peaked at $3.58K in Q2 2024. 235 funds tracked by Wall St. Rank hold CRNX as of Q3 2024.

  • Ashton Thomas Private Wealth reported no remaining Crinetics Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Ashton Thomas Private Wealth sold 80 Crinetics Pharmaceuticals shares in Q3 2024, an estimated $3.58K.
  • Ashton Thomas Private Wealth first reported a position in Crinetics Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Ashton Thomas Private Wealth's Crinetics Pharmaceuticals position peaked at $3.58K in Q2 2024.
  • 235 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2024.

Based on Ashton Thomas Private Wealth's 13F filing for Q3 2024, filed 5 Nov 2024.